Canada markets closed

Provention Bio, Inc. (2VB.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
8.20+0.54 (+7.08%)
At close: 09:15AM CET

Provention Bio, Inc.

55 Broad Street
2nd Floor Red Bank
Red Bank, NJ 07701
United States
908 336 0360

Full Time Employees82

Key Executives

NameTitlePayExercisedYear Born
Mr. Ashleigh W. Palmer B.Sc., M.B.A.Co-Founder, Pres, CEO & Director900.3kN/A1963
Mr. Thierry ChaucheChief Financial Officer411.37kN/A1976
Dr. Eleanor L. Ramos M.D.Chief Medical Officer611.72kN/A1956
Dr. Francisco Leon M.D., Ph.D.Co-Founder & Chief Scientific OfficerN/AN/A1972
Ms. Christina YiChief Operations OfficerN/AN/A1976
Mr. Robert A. Doody Jr.VP of Investor RelationsN/AN/AN/A
Ms. Heidy Abreu King-Jones J.D., L.L.M.Chief Legal OfficerN/AN/A1983
Kaelan HollonVP of Corp. CommunicationsN/AN/AN/A
Mr. Jason LevineVP MarketingN/AN/AN/A
Sarah O'BrienChief People OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Corporate Governance

Provention Bio, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.